Combretastatin A4

Catalog No.S7783

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 NF\rWlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NET1UnJEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBUU02HTD21JI1mdGGwb33hJINmdGxibHnu[ZMtKEWGNUC9N{4xOEVvMEig{txO NYnJWHFwOTh5NUO1NC=>
A-549 MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIPCdJREgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBCNTV2OTDseY5oKGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwMkDFMVA3KM7:TR?= NIHZVHgyQDd3M{Ww
MCF-7 NFrq[nBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{LoRWN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1ETi15IHLy[YF{fCClYYLjbY5wdWFiY3XscEBtcW6nczygSWQ2OD1|LkiwSU0xPiEQvF2= MYSxPFc2OzVy
HT-29 MkTrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoSxR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gTHQuOjliY3;sc44h[WSnbn;jZZJkcW6xbXGgZ4VtdCCuaX7ld{whTUR3ME2xMlIxTS1yNjFOwG0> NVfOUIR6OTh5NUO1NC=>
MLM melanoma cell NULveIE1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDNUG0hdWWuYX7vcYEh[2WubDDsbY5meyxiRVS1NF0yNjRyRT2wOkDPxE1? MnzsNVg4PTN3MB?=
M14 NVi4UFV{S3m2b4TvfIlkcXS7IHHzd4F6 MY\JckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImge4F{KHSnc4Tl[EBi\2GrboP0JIh2dWGwIH3lcIFvd22jIHPhcoNmeiBqTUG0LUBk\WyuIHzpcoUtKEeLNUC9NE4xODBzIN88US=> MlHNNVI4Ojl4NEC=
SK-OV3 NUPzXJV{S3m2b4TvfIlkcXS7IHHzd4F6 NHj1PZZKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhfGW|dHXkJIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIhMFONLV;WN{kh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> NHjTZmEyOjd{OU[0NC=>
HL60 cells NIX4XJdEgXSxdH;4bYNqfHliYYPzZZk> MWi3NkBp MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFAyKM7:TR?= M1\PbFIxPzNzM{W1
SK-OV-3 NIjieIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX:0PEBp MkjDS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2suV1ZvMzDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwNVMh|ryP Mm\VNVg4OjJzMke=
HepG2 cells NIrrNYVEgXSxdH;4bYNqfHliYYPzZZk> Ml\4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMtKEmFNUC9NE4xODBzNDFOwG0> Mo\rNVcyOjdyNkG=
ZR-75-1 NYniSFhoS3m2b4TvfIlkcXS7IHHzd4F6 MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBbWi15NT2xJINmdGxibHnu[UwhUUN3ME2wMlAxODJ2IN88US=> NETzSZgyPzJ2OU[0PS=>
HeLa cell M1fmTmN6fG:2b4jpZ4l1gSCjc4PhfS=> NFHtO45EgXSxdH;4bYNqfHliYXfhbY5{fCCKZVzhJINmdGxibHnu[UwhUUN3ME2wMlAxODNizszN NWOzZlRCOTd{NEm2OFk>
HCT116 cell MXjDfZRwfG:6aXPpeJkh[XO|YYm= NX\4eVZzS3m2b4TvfIlkcXS7IHHnZYlve3RiSFPUNVE3KGOnbHygcIlv\SxiSVO1NF0xNjByMEO1JO69VQ>? MmPpNVczPDl4NEm=
KBV1 cells M4PPdWN6fG:2b4jpZ4l1gSCjc4PhfS=> NX3FT5VoPzJiaB?= M1LvXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJZqdmKuYYP0bY5mNXKnc3nzeIFvfCCNQm[xJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEC0JO69VQ>? M1q2ZlIxPzNzM{W1
SKOV3 MYrDfZRwfG:6aXPpeJkh[XO|YYm= NX7D[VB5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxPDJizszN MYWyOFAyPjByMh?=
SKOV3 cells Mn\NS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUn2N3J[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjByMESyJO69VQ>? M4PhN|I{Pzd{M{C5
HeLa cells M3nuUWN6fG:2b4jpZ4l1gSCjc4PhfS=> NVLydYxSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFA2OSEQvF2= NF;WR5kyQTh5OUe1PC=>
DU145 cells MWDDfZRwfG:6aXPpeJkh[XO|YYm= NEDzeJZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA2PCEQvF2= MXyyOFAyPjByMh?=
DU145 cells M3;EUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEPZXolIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVAvODByNUSg{txO NHXyUXIzOzd5MkOwPS=>
SK-N-BE NH;Cco1Rem:uaX\ldoF1cW:wIHHzd4F6 MXe3NkBp NU\LbIU2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hW0tvTj3CSUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVgh|ryP MXeyNlMzQTV4MR?=
NCIH460 cells NUmzb5lkS3m2b4TvfIlkcXS7IHHzd4F6 MoLrOFghcA>? NGXzSI5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0mKNE[wJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC2JO69VQ>? NVvHdINVOTh|MEO4OFk>
KB-VIN10 cells NWixTnhxWHKxbHnm[ZJifGmxbjDhd5NigQ>? MlHlO|IhcA>? MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHzzJI93\XJvZYjwdoV{e2mwZzDQMYdxKDF5MD;NSHIyKGGodHXyJFczKGi{czDifUBu\XSqeXzlcoUh[my3ZTDhd5NigSxiSVO1NF0xNjByMEeg{txO MVmyNVY1OTdyMB?=
HCT116 cells NHfwXGREgXSxdH;4bYNqfHliYYPzZZk> MlXHO|IhcA>? NWX2cJlzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCdM1jdeIh6dWmmaX7lJIlv[2:{cH;yZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTB;MD6wNFA4PCEQvF2= Mny3NlE6PTV2NUS=
DU145 cells NHzOZZZEgXSxdH;4bYNqfHliYYPzZZk> MkXnOFghcA>? NUXSeIVwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMEig{txO M{nueFE5OzB|OES5
RS4:11 cells NX64[ZZ3WHKxbHnm[ZJifGmxbjDhd5NigQ>? M4W2NlczKGh? M2fYXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmO0PlEyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTCoN{0pPCx3LXTpcYV1cHmudHjpZZpwdC1{LYnsLU0zNDVvZHnwbIVvgWy2ZYTyZZpwdGm3bTDido9ucWSnIITld5QtKEmFNUC9NE4xODB6IN88US=> NHLvb5kzPTd6NU[wOS=>
HCT 116 MoXqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH\RXGpEd26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCqdX3hckBkd2yxbjD0eY1weiCKQ2SgNVE3NCCLQ{WwQVAvODByOTFOwG0> MWexNVcyPDZzMx?=
HeLa cells MlKxR5l1d3SxeHnjbZR6KGG|c3H5 NGX5eWI4OiCq MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDy[ZNignW{aX6gZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTBwMECwPUDPxE1? NF7jOJIzPDZ4OUi4PC=>
BNL 1ME A.7R.1 cells NFvFfYJEgXSxdH;4bYNqfHliYYPzZZk> NUTsXGxvS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSk6OIEHNSUBCNjeULkGgZ4VtdHNuIFnDOVA:OC5yMEC5JO69VQ>? M4T6WVI2Pzh3NkC1
Calu6 NWHIeJdHWHKxbHnm[ZJifGmxbjDhd5NigQ>? M17Y[lQ5KGh? MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOjbIW2JIFnfGW{IES4JIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{eTygTWM2OD1yLkCwNFk1KM7:TR?= NVXH[I5IOjF5N{S0PVk>
melanoma B16 cell M4nKWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIrNTJBEd26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCvdYLpcoUhdWWuYX7vcYEhSjF4IHPlcIwhdGmwZTygTWM2OD1yLkCwNUDPxE1? M1nocVEyPzF2NkGz
DU145 cells MUTDfZRwfG:6aXPpeJkh[XO|YYm= MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO MWOyNFQ6Pjl{Mx?=
HCT116 cells M4fIT3Bzd2yrZnXyZZRqd25iYYPzZZk> M2LHelczKGh? MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? M4jVSFIyOTF{MUOw
HCT15 cells M2XpXXBzd2yrZnXyZZRqd25iYYPzZZk> MWS3NkBp M2Hle2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNUDPxE1? Mof1NlEyOTJzM{C=
HL60 cells NVnqNVJLWHKxbHnm[ZJifGmxbjDhd5NigQ>? NF:4b5A4OiCq NEHoO4VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= NGDIbI8zOTZ4M{OxPS=>
A10 cells NIXRfoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NY\uNYp2PDhiaB?= MVfHdo94fGhiaX7obYJqfGmxbjDv[kBz[XRiQUGwJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NGnHZ|gzOjB2NEG2OC=>
HUVEC cells NXX3fXdMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYG0PEBp MXXHdo94fGhiaX7obYJqfGmxbjDv[kBJXV[HQzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> M4L2[|IzODR2MU[0
HL60 cells M2fVOmN6fG:2b4jpZ4l1gSCjc4PhfS=> MljWO|IhcA>? MontR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M{frXFIzOTN4M{Gy
HL60 cells M4rQbXBzd2yrZnXyZZRqd25iYYPzZZk> MXO3NkBp MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? M{\MR|IzPTd6MUGx
NCI-H522 cells NUDKbIJqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF;FO4o1QCCq NXXFOI9YT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NHfCTYszOjl6MkGyNi=>
MDA-MB-435 cells MlOxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3L0fVQ5KGh? M13WNWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? Ml:5NlI6QDJzMkK=
OVCAR3 MmTGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1q2SlQ5KGh? NFS1TlRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBQXkODUkOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NVrpTYZTOjJ7OEKxNlI>
NCI/ADR-RES cells NV3rNY9xT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2fUb|Q5KGh? M33EUGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS:DRGKtVmVUKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP M{LVR|IzQTh{MUKy
PC3 cells NFrZc3dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml;lOFghcA>? M17JcGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= M3nBTVIzQTh{MUKy
DU145 cells MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVy0PEBp MnH3S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= MX2yNlk5OjF{Mh?=
MDA-MB-231 cells M4DZNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlzSOFghcA>? NU\VXodqT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= M{HCXFIzQTh{MUKy
CEM cells MXrDfZRwfG:6aXPpeJkh[XO|YYm= MX63NkBp MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MmTGNlI3PzZ{NEe=
HCT116 cells M4nRbmN6fG:2b4jpZ4l1gSCjc4PhfS=> MXG3NkBp NF\tbohEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> NWrqSJhGOjJ4N{[yOFc>
MDA-MB-435 cells M330cGN6fG:2b4jpZ4l1gSCjc4PhfS=> NWP6cm9kPzJiaB?= NVfXbmVLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NXP0SpBSOjJ4N{[yOFc>
HaCaT cells MWDQdo9tcW[ncnH0bY9vKGG|c3H5 MmTuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKYVPhWEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MknLNlMxPjN2MEG=
HL60 cells MYDQdo9tcW[ncnH0bY9vKGG|c3H5 MUe3NkBp MnfNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NH61S2czOzFzN{G3NS=>
HL60 cells MkftVJJwdGmoZYLheIlwdiCjc4PhfS=> NE\4fYE4OiCq Mlf0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSBqMz2oOEw2NWSrbXX0bJltfGirYYrvcE0zNXmuKT2yMFUu\GmyaHXufYx1\XS{YYrvcIl2dSCkcn;tbYRmKHSnc4SsJGlEPTB;MD6wNFEh|ryP Mkf1NlU4QDV4MEW=
HT-29 MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHj1XIJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NVq2[ot3OjV4OEmxNVE>
HL60 cells M4nEd3Bzd2yrZnXyZZRqd25iYYPzZZk> MXK3NkBp MmrMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NX\u[|NZOjB2MkC0N|k>
Hs578T cells Mnj5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmPyOFghcA>? MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDId|U4QFRiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= MlvENlI6QDJzMkK=
HL60 cells MnHVR5l1d3SxeHnjbZR6KGG|c3H5 MYG3NkBp NX74T3FWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> MWCyN|Q1PTR7Nh?=
SKOV3 cells NEfzTFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1\KdGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMV1Z|IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MmPDNlU3QDlzMUG=
MDA-MB-468 cells M2PyTmN6fG:2b4jpZ4l1gSCjc4PhfS=> NH;HWoE1KGSjeYO= MkmxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMECxNUDPxE1? Mnr3NlQzOTB3MEO=
MCF7 cells MmWwVJJwdGmoZYLheIlwdiCjc4PhfS=> NHv0VlA4OiCq NVHvWGFkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzMUGg{txO MX6yNlMzQTV4MR?=
H460 M{niNWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2XKWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg1PjBiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiC2ZYP0MEBKSzVyPUCuNFAyOiEQvF2= MXuxPFc5OzJyNx?=
H460 MnnYVJJwdGmoZYLheIlwdiCjc4PhfS=> MlHuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKNE[wJINmdGy|LDDJR|UxRTBwMECxNlQh|ryP MnLaNVY4OjJ4M{O=
NCI-H460 cells MoTjR5l1d3SxeHnjbZR6KGG|c3H5 NXjLfpBNPzJiaB?= NXfWRoRzS3m2b4TvfIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIhfGW|dDygTWM2OD1yLkCwNVMh|ryP M1XsVVE5Ozl4OEW3
OVCAR8 cells NUizTm9lT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYS5RW9KQTZiaB?= NH7tUoxIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBQXkODUkigZ4VtdHNib4\ldoV5eHKnc4PpcochWC2pbInjc5Bzd3SnaX6gZYZ1\XJiOU[gbJJ{NCCLQ{WwQVAvODBzMzFOwG0> NVjwWncyOjJyNESxOlQ>
NCI/ADR-RES cells MWXDfZRwfG:6aXPpeJkh[XO|YYm= MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBjgSC2conwZY4h[my3ZTDlfINtfXOrb36gZZN{[XluIFnDOVA:OC5yMEGzJO69VQ>? NIrkUlYzOzJzNES1Ni=>
OVCAR8 cells NGPuWFhEgXSxdH;4bYNqfHliYYPzZZk> M2jM[Fk3KGh? M33ZXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB7NjDodpMh[nliR3nlcZNiKHO2YXnubY5oNWKjc3XkJIxq\2i2IH3pZ5Jwe2OxcImsJGlEPTB;MD6wNFE{KM7:TR?= NYLLZ|JUOjVyMkW5PVE>
NCI/ADR-RES cells MoPkR5l1d3SxeHnjbZR6KGG|c3H5 NV7CNJFJQTZiaB?= NHzhUppEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA6PiCqcoOgZpkhT2mnbYPhJJN1[WmwaX7nMYJie2WmIHzp[4h1KG2rY4Lvd4NweHluIFnDOVA:OC5yMEGzJO69VQ>? MoG3NlUxOjV7OUG=
OVCAR8 cells NXLsfHhUS3m2b4TvfIlkcXS7IHHzd4F6 MmjIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHL5JJRzgXCjbjDicJVmKGW6Y3z1d4lwdiCjc4PhfUwhUUN3ME2wMlAxOTNizszN NVzPUWU5OjN{MUS0OVI>
HuTu 80 cells Mn76VJJwdGmoZYLheIlwdiCjc4PhfS=> M{XDXFczKGh? NX3NR4t{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hUHWWdTC4NEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxN|ch|ryP M3rB[|IzOzJ7NU[x
K562 cells Mli0R5l1d3SxeHnjbZR6KGG|c3H5 MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUCuNFAyPCEQvF2= M3;rZlE6QDN5NUm0
NCI/ADR (MDR) cells M2PJV2Z2dmO2aX;uJIF{e2G7 MVPD[YxtKGO7Y3zlJIFzemW|dDDpckBPS0lxQVTSJEhOTFJrIHPlcIx{KGK7IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnLDDJR|UxRTBwMECxOUDPxE1? NX6ySnhXOTZ|N{exPFc>
HUVEC MnLqVJJwdGmoZYLheIlwdiCjc4PhfS=> NH7iSphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVENCCLQ{WwQVAvODBzNTFOwG0> MofYNVY4OjJ4M{O=
KB cell MVfQdo9tcW[ncnH0bY9vKGG|c3H5 MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuEIHPlcIwhdGmwZTDifUBu\XSqeXzlcoUh[my3ZTDkfYUh[XO|YYmsJGlEPTB;MD6wNFE2KM7:TR?= NHTXe4UyPzB|NEG0Oy=>
KB-VIN10 cell MWTQdo9tcW[ncnH0bY9vKGG|c3H5 M3ruOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KtWmlPOTBiY3XscEBtcW6nIHL5JI1mfGi7bHXu[UBjdHWnIHT5[UBie3OjeTygTWM2OD1yLkCwNVUh|ryP NULuT2F6OTdyM{SxOFc>
Human SH-SY5Y neuroblastoma cells M3vReWZ2dmO2aX;uJIF{e2G7 NVzJRYhJUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgTJVu[W5iU1itV3k2YSCwZYXyc4Jt[XO2b33hJINmdGy|LDDJR|UxRTBwMECxOUDPxE1? MnHJNVU6PjN5MkK=
SW620 cells M1zlT3Bzd2yrZnXyZZRqd25iYYPzZZk> NX\OU|lNPzJiaB?= M361ZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJHNYPjJyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODF3MjFOwG0> MnXDNlI{Ojl3NkG=
Molt4/C8 cells M4nxTnBzd2yrZnXyZZRqd25iYYPzZZk> NV[yendESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNc4x1PC:FODDj[YxteyxiSVO1NF0xNjByMU[g{txO M{S2TFE4ODN2MUWw
ACHN cell M1\s[3Bzd2yrZnXyZZRqd25iYYPzZZk> NVjrSJZ6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBlenWpIILld4l{fGGwdDDBR2hPKGOnbHygcIlv\SCneIDy[ZN{cW6pIF3EVlEh[nliQXzhcYFzKEKudXWgZZN{[XluIFnDOVA:OC5yMEG2JO69VQ>? MkSwNVczQDZ|OUO=
Molt4/C8 cells NHvCVZZRem:uaX\ldoF1cW:wIHHzd4F6 MV:zJIRigXN? MYjBcpRqeHKxbHnm[ZJifGm4ZTDl[oZm[3RiYXfhbY5{fCCqdX3hckBOd2y2ND;DPEBk\WyuczDh[pRmeiB|IHThfZMtKEmFNUC9NE4xODF4IN88US=> NFzpU20yPzRzOU[wOy=>

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
+ Expand

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
+ Expand
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Formulation: DMSO
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395434 Completed Tumors Mateon Therapeutics September 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID